Blueberries Show Promise for Kids’ Mental Health, but the Science Is Still Catching Up

Nearly one in three American children now carries a mental, behavioral, or developmental diagnosis, and researchers are searching everywhere for scalable, low-risk strategies to help. A narrative review published in Nutrients by Lina Fan et al. examines whether blueberry bioactives, compounds like anthocyanins, flavonols, and phenolic acids, could play a supporting role in pediatric neurodevelopmental and emotional health. The short answer: early signals are intriguing, but the clinical evidence base is thin and direct proof in children with diagnosed disorders is largely missing.

Rising Childhood Mental Health Burden Demands New Adjunctive Tools

The lifetime prevalence of mental, behavioral, and developmental disorders among U.S. children aged 3 to 17 climbed from 25.3% in 2016 to 27.7% in 2021, driven by increases in anxiety, depression, learning disability, and developmental delay. That figure sits alongside a steady climb in ADHD and autism diagnoses: by 2024, 13.6% of children ages 5 to 17 had ever been diagnosed with ADHD, and 4.5% had autism. Standard pharmacological treatments help many children, but side effects and access barriers push families toward adjunctive options. Dietary interventions are appealing precisely because they are generally low-risk, affordable, and scalable, qualities that pharmacotherapy often is not.

Blueberries sit at the intersection of several active research threads: antioxidant biology, the gut-brain axis, and pediatric cognitive neuroscience. The review synthesizes evidence from human trials, animal models, and mechanistic studies published between January 2016 and March 2025.

What Blueberry Polyphenols Actually Do in the Brain

The bioactive compounds in blueberries are not passive nutrients. Anthocyanins, the pigments responsible for the fruit's deep color, and related polyphenols activate the Nrf2 pathway, a master switch for the body's endogenous antioxidant defenses. They also appear to suppress microglial activation and reduce pro-inflammatory cytokines, the signaling molecules that, when chronically elevated, are associated with impaired neuronal function.

Preclinical work points to effects on hippocampal synaptic plasticity and neurogenesis, processes central to learning and memory. Blueberry bioactives have also been linked to increased levels of neurotrophic factors like BDNF and NGF, proteins that support neuron survival and growth. In aged mice given high-dose anthocyanin treatment, brain dopamine levels increased and anxiety-like behaviors decreased. These are animal findings under high-dose conditions, so extrapolating them directly to children requires caution.

A separate line of evidence runs through the gut. Colonic bacteria metabolize anthocyanins into smaller bioactive compounds that may influence the gut-brain axis by modulating tryptophan metabolism and short-chain fatty acid production. In one animal model using an anthocyanin-rich blueberry extract, autism-like behaviors decreased alongside reductions in neuroinflammation, gut inflammation, and normalization of gut microbiota, with serotonin levels rising. Again, this is preclinical data, but it maps onto a plausible mechanism.

Human Trial Results in Children Are Promising but Modest

The most clinically relevant findings come from randomized controlled trials in typically developing children, not in those with diagnosed disorders. One trial found that a flavonoid-rich wild blueberry beverage improved memory and executive function acutely in healthy children aged 7 to 10. Positive affect increased within two hours of consumption. Faster reaction times on attention tasks appeared without any drop in accuracy. Verbal memory, including immediate and delayed recall, also improved.

A systematic review of blueberry randomized controlled trials found that eight studies reported cognitive improvements, particularly in short- and long-term memory, with low risk of bias across the included studies. In adolescents aged 12 to 17 with subclinical depression, four weeks of daily wild blueberry powder supplementation reduced depressive symptoms. One trial found that wild blueberry powder shifted the gut microbiome of healthy children toward higher Bacteroidetes and lower Firmicutes, a ratio that tends to be inverted in children with ASD and correlates with behavioral abnormalities.

Higher anthocyanin doses consistently produced better cognitive outcomes than lower ones, and effects appeared within hours in some studies. European bilberry (Vaccinium myrtillus) typically contains three to five times more anthocyanins than the common North American highbush blueberry (V. corymbosum), a detail that matters considerably when interpreting dose-response data across studies.

Key Gaps: No Trials in Diagnosed Pediatric Populations

The review is candid about what the evidence does not yet show. Every clinical trial it cites was conducted in typically developing children or adolescents with subclinical, not clinically diagnosed, conditions. There are no published randomized controlled trials testing blueberry or anthocyanin supplementation in children formally diagnosed with ASD, ADHD, or clinical depression.

Systemic bioavailability of anthocyanins is generally low, and whether enough reaches the central nervous system in children to produce the effects seen in animal models has not been established. Definitive mechanisms of action for cognitive improvements remain unknown, especially in children, and the high-dose, acute protocols used in many animal studies do not map cleanly onto real-world pediatric dietary patterns. Pediatric dose-response data for concentrated blueberry supplements are limited, and age-appropriate intake levels are not formally defined. Potential interactions with stimulants or SSRIs are speculative and have not been systematically investigated.

Processing also degrades anthocyanins. Heat, light, and pH shifts all reduce potency, so the form of blueberry consumed, whole fruit, juice, freeze-dried powder, or encapsulated extract, affects how much bioactive material actually reaches the gut. Microencapsulation using natural polysaccharides or plant proteins can protect anthocyanins and improve colon delivery, but these delivery systems add cost and complexity.

What Research Needs to Happen Next

The review points toward several priorities. Trials in clinically diagnosed pediatric populations are the obvious gap: researchers need to test whether the cognitive and mood effects seen in healthy children translate to those with ASD, ADHD, or depressive disorders. NIH has identified the role of diet and nutritional status in the etiology of pediatric neurodevelopmental disorders as a high-priority research area, which suggests funding interest is aligned.

Longer intervention periods are also needed. Four weeks of supplementation in subclinically depressed adolescents is a starting point, not a conclusion. Pharmacokinetic studies examining how anthocyanins interact with common pediatric medications would help clinicians counsel families who are already combining dietary strategies with pharmacotherapy.

For now, whole blueberries in a child's diet carry essentially no risk and a plausible biological rationale. Concentrated supplements are a different question, one that still needs careful study before they can be recommended alongside standard care for neurodevelopmental or behavioral disorders.

Evidence rating

INVESTIGATIONAL — 75/100

Caveats:

• This is a narrative review, not a clinical trial — it summarizes existing studies rather than generating new experimental data, and no formal risk-of-bias assessment was performed.
• Almost all clinical evidence comes from typically developing children or subclinical populations; children with diagnosed ADHD, ASD, or mood disorders have not been adequately studied.
• Anthocyanins have low bioavailability, and whether meaningful amounts reach the brain or gut in children at realistic dietary doses has not been established.
• Several supporting findings come from animal models or in vitro studies that cannot be directly extrapolated to children.
• Funding source was not disclosed by the authors.

Narrative review synthesizing literature from 2016–2025 across human, animal, and in vitro studies; no meta-analysis or formal risk-of-bias assessment was conducted. The available clinical trials involve small samples of typically developing children and adolescents, limiting generalizability, and the mechanistic pathway from anthocyanin ingestion to CNS effect has not been fully demonstrated in humans. Findings are promising but not yet replicated in clinically diagnosed pediatric populations.

References

1. Lina Fan, Shuwei Wei, Xing Yang, et al. (2026). Blueberry Bioactives as Adjunctive Nutritional Strategies for Pediatric Neurodevelopmental and Emotional–Behavioral Health: Mechanisms, Evidence, and Translational Challenges. Nutrients. https://doi.org/10.3390/nu18132039
2. Rebecca T. Leeb, Melissa L. Danielson, Angelika H. Claussen, et al. (2024). Trends in Mental, Behavioral, and Developmental Disorders Among Children and Adolescents in the US, 2016–2021. Preventing Chronic Disease. https://doi.org/10.5888/pcd21.240142
3. Health – Neurodevelopmental Disorders | US EPA. epa.gov. https://www.epa.gov/health-indicators/health-neurodevelopmental-disorders
4. Diana Serra, Joana F. Henriques, Fábio J. Sousa, et al. (2022). Attenuation of Autism-like Behaviors by an Anthocyanin-Rich Extract from Portuguese Blueberries via Microbiota–Gut–Brain Axis Modulation in a Valproic Acid Mouse Model. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms23169259
5. Katie L. Barfoot, Gabrielle May, Daniel J. Lamport, Jessie Ricketts, Patricia M. Riddell, Claire M. Williams (2018). The effects of acute wild blueberry supplementation on the cognition of 7–10-year-old schoolchildren. European Journal of Nutrition. https://doi.org/10.1007/s00394-018-1843-6
6. Nikolaj Travica, Nathan M. D'Cunha, Nenad Naumovski, et al. (2020). The effect of blueberry interventions on cognitive performance and mood: A systematic review of randomized controlled trials. Brain, Behavior, and Immunity. https://doi.org/10.1016/j.bbi.2019.04.001
7. Katie L. Barfoot, Gabrielle May, Daniel J. Lamport, Jessie Ricketts, Patricia M. Riddell, Claire M. Williams (2018). The effects of acute wild blueberry supplementation on the cognition of 7–10-year-old schoolchildren. European Journal of Nutrition. https://doi.org/10.1007/s00394-018-1843-6
8. Understanding Nutritional Influences on Neurodevelopmental Disorders in Children. NIH. https://grants.nih.gov/grants/guide/rfa-files/RFA-ES-23-009.html